American Century Companies Inc. Acquires 8,985 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

American Century Companies Inc. raised its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 17.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,710 shares of the company’s stock after purchasing an additional 8,985 shares during the quarter. American Century Companies Inc.’s holdings in Entrada Therapeutics were worth $1,032,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TRDA. Geode Capital Management LLC lifted its holdings in Entrada Therapeutics by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after buying an additional 46,512 shares in the last quarter. Barclays PLC boosted its holdings in shares of Entrada Therapeutics by 210.6% in the third quarter. Barclays PLC now owns 45,110 shares of the company’s stock valued at $720,000 after purchasing an additional 30,585 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after purchasing an additional 3,644 shares in the last quarter. State Street Corp increased its holdings in Entrada Therapeutics by 5.5% during the 3rd quarter. State Street Corp now owns 469,601 shares of the company’s stock worth $7,504,000 after purchasing an additional 24,385 shares during the period. Finally, SG Americas Securities LLC raised its position in Entrada Therapeutics by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock valued at $243,000 after purchasing an additional 4,291 shares in the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Entrada Therapeutics Stock Down 5.1 %

Shares of NASDAQ:TRDA opened at $7.85 on Friday. The firm has a 50 day moving average of $10.92 and a 200 day moving average of $14.92. The company has a market capitalization of $295.12 million, a price-to-earnings ratio of 4.94 and a beta of 0.04. Entrada Therapeutics, Inc. has a 52 week low of $7.10 and a 52 week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $12.25 million during the quarter, compared to analysts’ expectations of $11.95 million. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Monday, March 31st.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.